For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

To watch more expert insights and analysis on the latest market action ... Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with ...

Companies showing rapid sales growth and improving profit margins include Eli Lilly, Micron, AMD and Newmont Every quarter during earnings season it can be useful to see which companies have improved ...

To watch more expert insights and analysis on the latest market action ... GE Vernova and TKO Group Holdings. Eli Lilly stock is hugging its 10-week moving average in a long base, while GE Vernova and ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

The stock should perform well beyond 2030 thanks to its impressive innovative abilities. With a constellation of ...

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial. The detailed ...